Cresco LabsFRA:6CQ -2.15%38 Days Payable is 18.34 as of Mar. 2026, which is 25% below its 10-year median of 24.51. GuruFocus rates FRA:6CQ with a GF Score™ of 38/100 and a GF Value™ of €0.78 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 922 Drug Manufacturers companies, Cresco Labs ranks worse than 95.77% on this metric.
The historical rank and industry rank for Cresco Labs's Days Payable or its related term are showing as below:
FRA:6CQ'
s Days Payable Range Over the Past 10 Years
Min: 16.88 Med: 24.51 Max: 92.59
Current: 19.2
During the past 13 years, Cresco Labs's highest Days Payable was 92.59. The lowest was 16.88. And the median was 24.51.
FRA:6CQ's Days Payable is ranked worse than 95.77% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.61
vs FRA:6CQ: 19.20
Cresco Labs's Days Payable
increased
from Mar. 2025 (16.96) to Mar. 2026 (18.34).
It may suggest that Cresco Labsdelayed paying its suppliers.
Cresco Labs Days Payable Related Terms
Cresco Labs Days Payable Historical Data
* Premium members only.
The historical data trend for Cresco Labs's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cresco Labs's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cresco Labs Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cresco Labs's Days Payable distribution charts can be found below:
* The bar in red indicates where Cresco Labs's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cresco Labs's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cresco Labs (FRA:6CQ) has a Days Payable of 18.34 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cresco Labs and its competitors. This is 25% below median its historical median of 24.51. Over the past decade, Cresco Labs' Days Payable has ranged from 16.88 to 92.59. According to the industry distribution chart, Cresco Labs ranks #883 out of 922 companies in the Drug Manufacturers industry, placing it in the top 95.8%.
Is Cresco Labs' Days Payable too high?
Cresco Labs' current Days Payable of 18.34 is 25% below median its 10-year median of 24.51. Over the past 10 years, this metric has ranged from a low of 16.88 to a high of 92.59. The Drug Manufacturers industry median Days Payable is 90.61. Cresco Labs' value of 18.34 is 79.8% below this industry median. Based on the distribution chart, Cresco Labs ranks #883 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cresco Labs has a GF Score™ of 38/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cresco Labs' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cresco Labs ranks #883 out of 922 companies for Days Payable. This places Cresco Labs in the lower half of its industry. The industry median Days Payable is 90.61. Cresco Labs' value of 18.34 is 79.8% below this benchmark. Historically, Cresco Labs' own Days Payable has ranged from 16.88 to 92.59 over the past decade. While the company's 10-year median is 24.51 vs. the industry median of 90.61, Cresco Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.61, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cresco Labs's current Days Payable of 18.34 is 79.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cresco Labs and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cresco Labs's current Days Payable is 18.34, which is 25% below median its own 10-year median of 24.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cresco Labs stock overvalued right now?
Based on GuruFocus' analysis, Cresco Labs (FRA:6CQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.78, compared to a current price of €0.68 — trading 12.3% below its estimated fair value. The current Days Payable is 18.34, which is 25% below median its 10-year median of 24.51 and 79.8% below the Drug Manufacturers industry median of 90.61. Cresco Labs' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cresco Labs (FRA:6CQ), the current Days Payable is 18.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cresco Labs (FRA:6CQ) Overvalued in 2026?
Based on GuruFocus' analysis, Cresco Labs stock appears to be undervalued.
The current stock price of €0.68 is trading 12.3% below its estimated GF Value™ of €0.78.
GuruFocus considers Cresco Labs to be Modestly Undervalued.
Key valuation signals for FRA:6CQ:
Days Payable: 18.34 (25% below median its 10-year median of 24.51)
GF Value™: €0.78 vs. price of €0.68 (12.3% below fair value)
Industry Position: 79.8% below the Drug Manufacturers median (#883 of 922)
No single metric tells the full story. See the FRA:6CQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cresco Labs Inc is a vertically-integrated multi-state cannabis operator in the United States licensed to cultivate, manufacture, and sell retail and medical cannabis products through Sunnyside, Cresco Lab's national dispensary brand, and others. The company operates in one segment: the cultivation, manufacturing, distribution, and sale of cannabis. The company's brand includes: Cresco, High Supply, FloraCal Farms, Good News, Wonder Wellness Co., Mindy's, and Remedi.
38GF Score
Get the complete analysis for FRA:6CQ
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6CQ has been successfully added to your 
